Insmed Inc
Company Profile
Business description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Contact
700 US Highway 202/206
BridgewaterNJ08807
USAT: +1 908 977-9900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,664
Stocks News & Analysis
stocks
3 ASX opportunities after earnings season
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,793.40 | 1.40 | -0.02% |
| CAC 40 | 7,935.97 | 24.44 | 0.31% |
| DAX 40 | 23,564.01 | 116.72 | 0.50% |
| Dow JONES (US) | 46,946.41 | 387.94 | 0.83% |
| FTSE 100 | 10,317.69 | 56.54 | 0.55% |
| HKSE | 25,834.02 | 368.42 | 1.45% |
| NASDAQ | 22,374.18 | 268.82 | 1.22% |
| Nikkei 225 | 53,751.15 | 68.46 | -0.13% |
| NZX 50 Index | 13,205.78 | 41.20 | 0.31% |
| S&P 500 | 6,699.38 | 67.19 | 1.01% |
| S&P/ASX 200 | 8,583.40 | 7.80 | 0.09% |
| SSE Composite Index | 4,084.79 | 10.66 | -0.26% |